Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection
- PMID: 20070407
- DOI: 10.1111/j.1468-1293.2009.00785.x
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection
Abstract
Objectives: We investigated the clinical significance of monitoring the mid-dosing interval atazanavir (ATV) concentration (measured 12 +/- 2 h after intake; C(12 h)) in patients taking this drug once daily in the evening.
Methods: We retrospectively selected HIV-infected patients harbouring ATV-susceptible virus who underwent therapeutic drug monitoring (TDM) of ATV C(12 h) during routine out-patient visits, and we correlated C(12 h) to the 24-week virological response and toxicity.
Results: A total of 115 plasma samples from 86 patients (76.7% with baseline HIV RNA<50 HIV-1 RNA copies/mL) were analysed. ATV plasma concentrations showed high inter-individual variability. ATV plasma levels were higher in samples obtained from patients taking boosted regimens (P<0.001) and not concomitantly receiving acid-reducing agents (P=0.007). In a multivariate model, ritonavir boosting, use of acid-reducing agents and liver cirrhosis showed an independent association with ATV level. Virological response at 24 weeks was observed for 94 of the 115 samples (81.7%). We identified a concentration cut-off of 0.23 mg/L which predicted virological response at 24 weeks: samples with a C(12 h)< or =0.23 mg/L showed virological failure in 41.2% of cases, whereas samples with a C(12 h)>0.23 mg/L showed virological failure in 14.3% of cases (P=0.021). In multivariate analysis, C(12 h)>0.23 mg/L was an independent predictor of virological response [odds ratio (OR) 4.23, P=0.031]. ATV levels correlated with concomitant unconjugated bilirubin levels (r=0.223, P=0.037), but a concentration cut-off predictive of moderate/severe hyperbilirubinaemia could not be identified.
Conclusions: We identified a C(12 h) efficacy threshold that predicted virological response; this could be useful for morning TDM in selected subjects receiving ATV in the evening. Results must be interpreted with caution given the retrospective design of the study.
Similar articles
-
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.New Microbiol. 2005 Apr;28(2):119-25. New Microbiol. 2005. PMID: 16035256 Clinical Trial.
-
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.Ther Drug Monit. 2007 Oct;29(5):648-51. doi: 10.1097/FTD.0b013e31815704c1. Ther Drug Monit. 2007. PMID: 17898658
-
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).Antivir Ther. 2006;11(4):421-9. Antivir Ther. 2006. PMID: 16856615 Clinical Trial.
-
[Clinical utility of atazanavir].Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:55-67. doi: 10.1016/S0213-005X(08)76622-9. Enferm Infecc Microbiol Clin. 2008. PMID: 20116619 Review. Spanish.
-
[Efficacy of atazanavir in treatment-naive patients].Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:9-13. doi: 10.1016/S0213-005X(08)76614-X. Enferm Infecc Microbiol Clin. 2008. PMID: 20116611 Review. Spanish.
Cited by
-
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.Clin Infect Dis. 2011 May;52(10):1267-75. doi: 10.1093/cid/cir131. Clin Infect Dis. 2011. PMID: 21507924 Free PMC article.
-
Clinically significant drug interactions with antacids: an update.Drugs. 2011 Oct 1;71(14):1839-64. doi: 10.2165/11593990-000000000-00000. Drugs. 2011. PMID: 21942976 Review.
-
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25. J Antimicrob Chemother. 2014. PMID: 25159623 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of antiretroviral drugs in older persons.Expert Opin Drug Metab Toxicol. 2013 May;9(5):573-88. doi: 10.1517/17425255.2013.781153. Epub 2013 Mar 20. Expert Opin Drug Metab Toxicol. 2013. PMID: 23514375 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials